Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.